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Abstract
Background: Cachexia is one of the most important causes of cancer-related death. Supplementation with
branched-chain amino acids, particularly leucine, has been used to minimise loss of muscle tissue, although few
studies have examined the effect of this type of nutritional supplementation on the metabolism of the tumour-
bearing host. Therefore, the present study evaluated whether a leucine-rich diet affects metabolomic derangements
in serum and tumour tissues in tumour-bearing Walker-256 rats (providing an experimental model of cachexia).
Methods: After 21 days feeding Wistar female rats a leucine-rich diet, distributed in L-leucine and LW-leucine
Walker-256 tumour-bearing groups, we examined the metabolomic profile of serum and tumour tissue samples
and compared them with samples from tumour-bearing rats fed a normal protein diet (C – control; W – tumour-
bearing groups). We utilised 1H-NMR as a means to study the serum and tumour metabolomic profile, tumour
proliferation and tumour protein synthesis pathway.
Results: Among the 58 serum metabolites examined, we found that 12 were altered in the tumour-bearing group,
reflecting an increase in activity of some metabolic pathways related to energy production, which diverted many
nutrients toward tumour growth. Despite displaying increased tumour cell activity (i.e., higher Ki-67 and mTOR
expression), there were no differences in tumour mass associated with changes in 23 metabolites (resulting from
valine, leucine and isoleucine synthesis and degradation, and from the synthesis and degradation of ketone bodies)
in the leucine-tumour group. This result suggests that the majority of nutrients were used for host maintenance.
Conclusion: A leucine rich-diet, largely used to prevent skeletal muscle loss, did not affect Walker 256 tumour
growth and led to metabolomic alterations that may partially explain the positive effects of leucine for the whole
tumour-bearing host.
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Background
Cancer is a worldwide health problem associated with
an increasing number of deaths every year. Cachexia is
one of the leading causes of death in cancer patients,
accounting for nearly 30 % of such cases [1–3], and is a
complex metabolic and nutritional syndrome charac-
terised by involuntary weight loss that is mainly due to
the wasting of skeletal muscle tissue. This muscle loss
is also accompanied by adipose tissue loss, weakness
affecting patient functional status and impairment of
the immune system, which ultimately lead to a very
poor quality of life and impaired host response to
treatment [2, 4, 5].
Cancer cachexia also leads to metabolic derangements,
and an increasing number of studies are emerging that
examine altered metabolite profiles associated with vari-
ous diseases, especially for cancer-associated cachexia [6].
Given that metabolites are excellent biomarkers, the
presence and quantity of specific metabolites may provide
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a better understanding of cancer cell biology [7, 8]. For ex-
ample, Der-Torossian and colleagues [7] described the
changes between cachectic and non-cachectic gastrocne-
mius muscle tissue from C26 tumour-bearing mice and
found that the glycolytic pathway was markedly altered
from that of healthy mice. Additionally, Shen and col-
leagues [8] reported potential biomarkers in the urine of
Walker-256 tumour-bearing rats during cancer progres-
sion, hypothesising that this alteration might have resulted
from elevated cell proliferation, a reduction in the ß-oxi-
dation of fatty acids and poor renal tubular reabsorption.
The use of metabolomic science importantly permits a
global understanding of biochemical processes and cellu-
lar states, reflecting changes in phenotype and also in
cellular or tissue function [6, 9, 10]. The identities, con-
centrations and fluxes of metabolites are the final product
of interactions between gene expression, protein expres-
sion and the cellular environment [11] and can therefore
serve as indicators of the overall physiological status of
patients [12].
Because cancer cachexia promotes metabolic alter-
ations that lead to poor quality of life, it is imperative to
increase the number of studies on and treatments for
cachexia to improve patient care. One promising area of
research is related to the use of nutritional supplementa-
tion to counteract physical changes accompanying
disease [13]. For example, supplementation with the
branched-chain amino acid has been shown to contrib-
ute to improved skeletal muscle mass that is diminished
with ageing or due to diseases such as AIDS and
diabetes [14]. Indeed, leucine is known to play an im-
portant role in skeletal muscle metabolism and regulates
protein synthesis in following food intake, stimulating
the mTOR pathway and inhibiting the ubiquitin-
proteasome pathway [15, 16]. Leucine alone as well as a
complete branched-chain amino acid mixture can fur-
ther stimulate protein synthesis and decrease protein
proteolysis [17]. Furthermore, previous studies from our
group have shown that a leucine-rich diet can improve
nitrogen balance and lean body mass [14, 18–20], specif-
ically the skeletal muscle [18, 21–30], placental and heart
[31] tissues in Walker 256 tumour-bearing rats. Thus,
leucine supplementation may also be promising for the
treatment and even prevention of cancer cachexia. Even
still, while the role of leucine in stimulating skeletal
muscle protein synthesis is well established in the litera-
ture [15, 17, 21, 32, 33], to date no study has evaluated
the leucine-induced modulation on metabolomic profile
in tumour-bearing hosts. In the present study, we
develop a 1H NMR metabolomic profile (serum and
tumour tissue) to evaluate the therapeutic effect of a
leucine-rich diet in rats bearing Walker 256 tumours,
which offer an experimental model of cachexia [34]. In this
way, we are able to evaluate the metabolic derangements
caused by tumour growth, and such knowledge may opti-
mise the ability to treat changes in molecular and




Female Wistar rats (approximately 90 ± 10 days old, ob-
tained from the Animal Facilities at the State University
of Campinas, UNICAMP, Brazil) weighing approximately
265 ± 10 g were housed in collective cages under con-
trolled environmental conditions (light and dark 12/12
h; temperature 22 ± 2 °C; and humidity 50-60 %). The
animals were monitored daily, weighed 3 times/week
and received food and water ad libitum. Semi-purified
diets were constructed in accordance with American Insti-
tute of Nutrition (AIN-93; [35]) while the leucine-
supplemented diet was enriched with 3 % L-Leucine as in
our previous works [14, 21, 24]. Both diets (control, C and
leucine, L) contained similar amounts of nitrogen (approxi-
mately 2.84 g N2/100 g diet) for a protein content of
approximately 18 %. All components of the diets are
presented in Table 1.
Walker 256 tumour inoculation
This study employed the Walker 256 tumour, which is
widely used as an experimental model of cancer cachexia
syndrome. Walker 256 carcinoma cells (2.5 × 106 viable
cells) were injected subcutaneously into the right flank
of the experimental rats on the first day of the experi-
ment. The general guidelines of the UKCCCR (United








Fibre (cellulose micro fibre) 5.0 5.0
Salt mix 3.5 3.5
Vitamin mix 1.0 1.0
Cysteine 0.3 0.3
Choline 0.25 0.25
Fat (soy oil) 7.0 7.0
L-leucine b 0.0 3.0
aProvided by Ingredion Products Brazil, bProvided by Ajinomoto
Interamericana Ind. & Com. Ltda. The diets contained similar amounts of
nitrogen (approximately 13.2 mg N2/100 g food). The caloric adjustment of the
amino acid-rich diet was accomplished by reducing the equivalent amount of
carbohydrates that corresponded to isocaloric diets. The other ingredients
contained the same amount of fat, fibre, salt and vitamin mix and cysteine
and choline as the normo-protein diet
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Kingdom Co-ordinating Committee on Cancer Research,
1998) [36] regarding animal welfare were followed, and
the experimental protocols were approved by the Institu-
tional Committee for Ethics in Animal Research (CEEA/
IB/UNICAMP, protocol # 2677-1).
Experimental protocol
Thirty-five animals were randomly distributed into four
experimental groups according to tumour implant status
and nutritional leucine supplementation: two groups
were fed a control diet (18 % protein): C, control
group (n = 9) and W, Walker 256 tumour-bearing
group (n = 9), while the other two other groups were
fed a leucine-rich diet (18 % protein + 3 % leucine): L,
leucine control group (n = 8) and LW, leucine Walker
256 tumour-bearing group (n = 9). All rats were moni-
tored and weighed 3 times/week. At the end of the
nutritional supplementation period, i.e., 21 days after
tumour evolution, the animals were sacrificed without
an overnight fast, their blood was collected, and tu-
mours were resected and weighed. Blood samples
were centrifuged at 1000 × g at 4 °C for 10 min and
serum was stored at −20 °C for metabolomic analyses.
The tumour tissue samples were frozen directly in
liquid nitrogen and stored at −80 °C for metabolomic
assays, western blotting and immunochemistry.
Metabolomic analysis
Sample preparation for NMR analysis
Plasma samples were filtered through a Microcon YM-3
column (Amicon Ultra 0.5 mL, Sigma-Aldrich) with a 3-
kDa membrane centrifuge filter for serum recovery (at 4
°C). Serum (0.2 mL) was diluted in an aqueous solution
(0.6 mL) containing 10 % (v/v) deuterium oxide (D2O,
99.9 %; Cambridge Isotope Laboratories Inc., Massachu-
setts, USA), phosphate buffer (0.1 M, pH 7.4) and 0.5
mM TMSP-d4 (3-(trimethylsilyl)-2,2',3,3'-tetradeutero-
propionic acid from Sigma-Aldrich), then transferred to
a 5-mm NMR tube (Norell Standard Series 5 mm,
Sigma-Aldrich) for immediate acquisition.
Tumour samples were processed following Le Belle
and colleagues’ protocol [37]. Briefly, tumour tissue frag-
ments were weighed, added to a cold methanol/chloro-
form solution (2:1 v/v, total of 2.5 mL) and sonicated
(VCX 500, Vibra-Cell, Sonics & Material Inc., USA) for
3 min with a 10-s pause interval between each minute.
A cold chloroform/distilled water solution (1:1 v/v, total
of 2.5 mL) was then added to the samples. Samples were
briefly vortexed (to form an emulsion) and centrifuged
at 3.1 × 103 g for 20 min at 4 °C. The upper phase (con-
taining methanol, water and polar metabolites) was
collected and dried in a vacuum concentrator (miVac
Duo Concentrator, GeneVac, UK). The remaining solid
phase was rehydrated in 0.6 mL of D2O-containing
phosphate buffer (0.1 M, pH 7.4) and 0.5 mM of TMSP-
d4. Samples were added to a 5-mm NMR tube for im-
mediate acquisition.
NMR data acquisition and metabolite identification
1H NMR spectra of samples were acquired using a
Varian Inova NMR spectrometer (Agilent Technologies
Inc., Santa Clara, USA) equipped with a triple resonance
probe and operating at a 1H resonance frequency of 500
MHz and constant temperature of 298 K (25 °C). A total
of 256 free induction decays were collected with 32-k
data points over a spectral width of 16 ppm. A 1.5-s re-
laxation delay was incorporated between scans, during
which a continual water presaturation radio frequency
(RF) field was applied. Spectral phase and baseline cor-
rections, as well as the identification and quantification
of metabolites present in samples, were performed using
Chenomx NMR Suite 7.6 software (Chenomx Inc.,
Edmonton, Canada).
Tumour immunohistochemistry for tumour Ki-67 and
vessel number
Fragments of tumour tissue were fixed for 24 h in 4 %
paraformaldehyde solution before being embedded in
paraffin. From each tissue sample, 5-μm sections were
selected for the Ki-67 immunoperoxidase reaction. For
the immunohistochemistry assay, the paraffin was re-
moved. For antigen retrieval, the sections were incu-
bated with 10 mM sodium citrate buffer (pH 6) for 1 h
at 80 °C, washed with 0.05 M Tris-buffered saline (TBS,
pH 7.4) and incubated with TBS containing 0.3 % H2O2
for endogenous peroxidase activity blockade. The sec-
tions were then permeabilised for 1 h with 0.1 % Tween®
20 and 5 % of fat-free milk in TBS. The sections were
then incubated with a rabbit monoclonal anti-Ki67 (1:50;
Spring Bioscience, Pleasanton, CA) antibody at 4 °C
overnight and, after this period, incubated with anti-
rabbit for rat tissues (Simples Stain Rat Max Po; N-
Histofine®; Nichirei Biosciences inc., Tokyo, Japan) for
1.5 h. The positive proliferating cells were detected with
3,3'-diaminobenzidine (DAB; Sigma- Aldrich Chemicals,
St Louis, MO, USA) solution (10 % DAB and 0.2 %
H2O2 in TBS). Finally, the sections were stained with
Ehrlich’s haematoxylin and mounted for microscopy.
The Ki67-positive cells were counted using Image-Pro
Plus software after capturing the image on a Leica
microscope using 100× magnification. For negative con-
trols, tumour sections from each group were incubated
in PBS without the first antibody and then incubated
with the biotinylated anti-goat secondary antibody
followed by reaction with DAB, as described above. The
number of positive cells and vessel number were deter-
mined by counting 5 fields (500 μm2 each) in one slide
from each of at least six rats per group.
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Tumour western blotting
Tumour tissue samples were homogenised in protein ex-
traction buffer (20 mM N-2-hydroxy ethylpiperazine-N-
2-ethanesulfonic acid, 100 mM KCl, 0.2 mM EDTA, 2
mM EGTA, 1 mM dithiothreitol, 50 mM NaF, 1 mM
DAB tetrahydrochloride, 0.5 mM orthovanadate and 50
mM glycine, pH 7.4) followed by centrifugation at
10,000 × g for 15 min at 4°C and were then separated by
10 % SDS–PAGE electrophoresis under reducing condi-
tions. After gel electrophoresis and protein transference
onto a nitrocellulose membrane, the proteins were
blocked at room temperature for 1 h in 5 % non-fat dry
milk. The membranes were then incubated overnight at
4 °C with antibodies against mTOR (Cell Signalling;
diluted 1:1000). Immunoreactivity was detected by the
sequential incubation of membranes with anti-mouse
secondary antibody for 1 h at room temperature, which
was visualised using a chemiluminescence detection
system. The level of mTOR was estimated versus the
constant level of the 50 kDa protein α-tubulin (Cell
Signalling; diluted 1:1000).
Statistical analyses
Results are shown as the mean ± standard deviation,
after analysis of all data by Graph Pad Prism 6.0 software
(Graph-Pad Software, Inc). For comparisons among mul-
tiple groups (e.g., C, W, L and LW), data were evaluated
with analysis of variance (two-way ANOVA) followed by
post-hoc comparison using Bonferroni’s test [38]. For
direct comparison between the two groups (e.g., analysis
of the tumour tissue in the W and LW groups), the data
were analysed using Student’s t-test. A significant differ-
ence was indicated for P ≤ 0.05. Metabolite set enrich-
ment analysis (MSEA) was performed to determine the
metabolic pathways impacted with the changed metabo-
lites among experimental groups. MSEA was conducted
using the MetaboAnalyst 3.0 tool, and a significant
difference was indicated for P ≤ 0.05 [39].
Results
Walker 256 tumour induced cachexia in both tumour-
bearing groups
Both tumour-bearing groups (W and LW) exhibited a
decrease in the rat carcass weight, a tumour weight to
body weight ratio higher than 10 % and a reduction in
serum albumin concentration (Table 2). Leucine supple-
mentation also leads to a lower cachexia index in the
LW group when compared with the W group. Under
our experimental conditions, this reduction trended to
reach significance with P = 0.0561 (Table 2).
Tumour weight and vessel number did not differ be-
tween the W and LW groups (Table 2 and Fig. 1a and
e), even though the tumour tissue of the LW group
showed an increase in mTOR and Ki-67 protein expres-
sion in comparison to W group (Fig. 1b, c and d).
Serum metabolomic alterations
In our 1H NMR metabolomics analysis system, which
mainly targeted water-soluble/polar metabolites, we de-
tected 58 metabolites in serum samples for all four experi-
mental groups. Among these metabolites, only 3 were
exclusive to tumour-bearing rats: 3-Methyl-2-oxovalerate,
4-Hydroxyphenyl Lactate and 3-Methylhistidine (Table 3).
Leucine was the only changed metabolite in the serum of
healthy animals fed a leucine-rich diet
In order to analyse the modulatory effect of nutritional
supplementation with leucine, we first analysed both
control groups (C and L) and found that leucine was the
only metabolite that increased in the L group in com-
parison with the C group (Table 3; Fig. 2a).
Walker 256 tumour growth induces a variety of changes
in metabolomic serum profile
A comparison of the tumour-bearing (W) and control (C)
groups showed changes in 12 metabolites (21.8 %), dem-
onstrating that the cancer cachexia severely affected me-
tabolism in the whole body (Table 3, Fig. 2b). Moreover,
Table 2 Morphometric parameters and cachexia indicators (a)
C (n = 9) W (n = 9) L (n = 8) LW (n = 9)
Morphometric parameters
Initial body weight (g) 253.4 ± 23.5 264.9 ± 14.6 249.4 ± 24.7 257.0 ± 16.5
Carcass weight (g) 247.5 ± 29.8 184.5 ± 33.7*, ** 243.8 ± 24.7 188.6 ± 21.8*, **
Cachexia index (a) - 63.9 ± 2.6 - 54.8 ± 2.9 ***
Tumour weight (g) - 36.04 ± 10.2 - 36.82 ± 9.0
Relative tumour weight (%)(b) - 14.79 ± 4.7 - 15.20 ± 4.8
Serum albumin (g/dL) 2.6 ± 0.2 1.5 ± 0.1* 2.7 ± 0.3 1.6 ± 0.2*, **
Data are expressed as the mean ± SD. Legend: C control; W, tumour-bearing (fed with control diet, 18 % protein); L, control; LW, tumour-bearing (fed with leucine-rich
diet, 18 % protein + 3 % leucine). Carcass weight represents the body weight without the weight of the gastrointestinal tract, liver, muscles and tumour. (a)Cachexia
index = [(initial body mass – carcass mass + tumour weight + body mass gain of control)/(initial body mass + body mass gain of control)] × 100 %. [1]. (b)Relative tumour
weight corresponds to the ratio of tumour and body weights, expressed as a percentage. *P ≤ 0.05 in comparison with the C group; **P ≤ 0.05 in comparison with the L
group; ***P = 0.0561 in comparison to the W group
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levels of the metabolites 2-oxoisocaproate, acetone, allan-
toin, sarcosine, tryptophan and 3-methylhistidine in-
creased in the W group relative to the C group while
arginine, glucose, glutamine, threonine and serine levels
decreased relative to the C group (Fig. 2b). With these al-
terations in serum metabolite levels, we found that four
metabolic pathways were significantly impacted (P ≤ 0.05)
due to the evolution of the Walker 256 tumour (Fig. 2b),
namely protein biosynthesis, glycine, serine and threonine
metabolism, ammonia recycling and the urea cycle.
Leucine-rich diet modulated the tumour-induced changes
in serum metabolomic profile
Tumour-bearing rats fed a leucine-rich diet (LW) showed
alterations in 23 (39.6 %) serum metabolites in comparison
to the control group (L) (Table 3 and Fig. 2c). Among these
metabolites, the levels of the following 16 were increased for
LW when compared with the L group: α-hydroxybutyrate,
2-hydroxyisovalerate, 2-oxoisocaproate, β-hydroxybutyrate,
3-hydroxyisobutyrate, acetoacetate, acetone, allantoin, beta-
ine, citrate, creatine, dimethylamine, tryptophan, o-acetylcar-
nitine, sarcosine, urea, 3-methylhistidine and myoinositol.
Only three metabolites decreased in the LW group: threo-
nine, glutamine and serine. We also observed that three
main pathways (P ≤ 0.05) were impacted by Walker 256
tumour evolution under a leucine-rich diet, namely glycine,
serine and threonine metabolism, ketone body metabolism
and valine, leucine and isoleucine degradation (Fig. 2c).
The leucine-rich diet modulated the impacted pathway
seen in tumour-bearing rats, leading to an increase in the
synthesis and degradation of ketone bodies
In order to evaluate the effect of the leucine-rich diet in









Fig. 1 Tumour parameters. a Tumour weight (g), b mTOR (Western Blot images represent the best results from 6 animals per group), c:
Immunohistochemistry image for Ki-67 protein (magnification 200×), d: Ki-67 expression and e: Number of vessels. For details, see Methods. The
graphics express the results as the mean ± SD.* P ≤ 0.05 for comparison with the W group
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Table 3 Serum metabolic concentration (μM)
Metabolites C (average ± SD) W (average ± SD) L (average ± SD) LW (average ± SD)
α-Aminobutyrate 5.8 ± 4.8 7.9 ± 1.8 4.5 ± 1.6 10.9 ± 7.2
2-Hydroxybutyrate 3.3 ± 2.8 24.7 ± 7.0 2.7 ± 0.8 32.5 ± 22.0 *, ***
2-Hydroxyisovalerate 0.9 ± 0.1 18.8 ± 5.7 1.0 ± 0.5 33.3 ± 25.1 *, ***
2-Oxoglutarate 5.4 ± 1.0 7.1 ± 1.1 5.1 ± 1.6 7.5 ± 2.5
2-Oxoisocaproate 0.6 ± 0.1 2.9 ± 0.9 * 0.9 ± 0.2 2.7 ± 0.5 *, ***
β-Hydroxybutyrate 14.5 ± 5.5 150.4 ± 70.3 22.9 ± 5.5 480.7 ± 278.3 *, **, ***
3-Hydroxyisobutyrate 8.6 ± 2.2 21.1 ± 6.5 7.0 ± 2.0 32.5 ± 17.5 *, ***
3-Methyl-2-oxovalerate 0.0 ± 0.0 4.4 ± 1.4 * 0.0 ± 0.0 3.4 ± 1.1 *, ***
4-Hydroxyphenyllactate 0.0 ± 0.0 2.8 ± 0.6 * 0.0 ± 0.0 6.8 ± 4.6 *, **, ***
Acetate 12.2 ± 2.1 33.3 ± 19.5 15.0 ± 4.5 35.0 ± 17.6
Acetoacetate 0.9 ± 0.4 3.4 ± 1.6 1.1 ± 0.4 7.6 ± 3.9 *, **, ***
Acetone 5.0 ± 0.7 61.6 ± 19.2 * 4.3 ± 1.6 53.3 ± 2.9 *, ***
Alanine 250.6 ± 33.4 477.5 ± 182.1 220.2 ± 53.3 419.9 ± 236.4
Allantoin 25.0 ± 2.5 132.2 ± 43.3 * 18.8 ± 14.6 156.4 ± 68.4 *, ***
Arginine 60.4 ± 2.1 37.4 ± 7.9 * 53.0 ± 16.3 38.9 ± 16.4
Asparagine 25.8 ± 1.7 18.7 ± 5.8 20.6 ± 5.4 19.4 ± 2.8
Aspartate 14.2 ± 1.6 12.2 ± 2.9 13.4 ± 4.2 18.1 ± 5.9
Betaine 34.9 ± 9.6 119.7 ± 61.0 30.9 ± 8.4 132.3 ± 86.1 *, ***
Carnitine 12.2 ± 1.5 15.3 ± 4.3 9.8 ± 3.2 17.7 ± 8.1
Choline 9.2 ± 2.0 16.2 ± 4.1 8.5 ± 2.5 20.4 ± 11.0
Citrate 70.8 ± 7.7 105.1 ± 22.1 57.3 ± 12.1 190.9 ± 112.2 ***
Creatine 87.1 ± 7.9 188.0 ± 43.0 73.4 ± 18.7 252.5 ± 138.1 *, ***
Creatinine 9.6 ± 0.8 12.7 ± 4.0 6.7 ± 2.6 21.7 ± 9.8
Dimethylamine 0.5 ± 0.2 2.2 ± 0.6 0.6 ± 0.1 4.6 ± 2.7 *, ***
Ethanol 874.3 ± 858.2 2159.4 ± 1079.9 949.5 ± 816.4 1257.7 ± 109.2
Formate 13.3 ± 8.4 31.0 ± 13.4 12.5 ± 1.8 27.9 ± 17.1
Fumarate 2.0 ± 0.3 1.3 ± 0.2 1.6 ± 0.3 1.4 ± 0.9
Glucose 1502.8 ± 171.0 708.7 ± 407.2 * 1305.1 ± 531.3 679.0 ± 479.3 *
Glutamate 68.7 ± 14.8 73.0 ± 15.8 71.1 ± 18.0 83.4 ± 34.6
Glutamine 258.3 ± 18.1 110.5 ± 33.0 * 224.7 ± 65.1 105.7 ± 45.5 *, ***
Glycerol 348.2 ± 61.1 266.4 ± 151.7 287.7 ± 53.5 193.9 ± 119.3
Glycine 80.2 ± 7.5 120.2 ± 37.2 67.0 ± 17.9 117.6 ± 31.6
Histidine 23.7 ± 2.6 24.2 ± 5.5 17.8 ± 4.2 24.7 ± 7.1
Isoleucine 31.7 ± 3.0 24.9 ± 4.9 21.9 ± 6.3 25.6 ± 10.7
Lactate 4201.1 ± 305.4 5007.8 ± 599.1 4133.7 ± 1165.8 4242.8 ± 684.4 **
Leucine 52.4 ± 5.5 43.5 ± 5.5 77.1 ± 13.6 * 59.7 ± 20.0
Lysine 236.6 ± 49.3 178.4 ± 55.7 204.9 ± 61.9 145.7 ± 59.3
Methionine 25.8 ± 5.2 22.3 ± 3.7 22.2 ± 6.0 19.3 ± 4.9
Dimethylglycine 2.3 ± 0.6 5.8 ± 2.4 1.9 ± 0.6 14.6 ± 11.9
O-Acetylcarnitine 4.7 ± 1.1 12.0 ± 2.8 3.7 ± 1.1 14.9 ± 6.7 *, ***
Ornithine 9.2 ± 0.8 13.7 ± 5.3 8.3 ± 3.2 22.9 ± 16.2
Pantothenate 1.8 ± 0.2 3.0 ± 1.0 1.9 ± 0.4 4.2 ± 2.9
Phenylalanine 21.0 ± 2.9 34.3 ± 5.9 18.8 ± 5.3 32.5 ± 12.0
Proline 113.5 ± 33.3 155.7 ± 60.6 96.7 ± 35.7 123.3 ± 50.4
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In the LW group, we found increased metabolites, such as
β-hydroxybutyrate (Fig. 3a), 4-hydroxyphenyllactate, acet-
oacetate (Fig. 3b) and urea, relative to the W group
(Table 3). Tryptophan and lactate levels also decreased in
the LW group compared to the W group (Table 3; Fig. 3c
and d). Analysing these changed metabolites, we observed
two main impacted pathways in LW groups namely butyr-
ate metabolism and ketone body metabolism (Fig. 2d).
Metabolomic profile of Walker 256 tumour tissue
Our 1H-NMR metabolomic analysis system largely tar-
geted water-soluble metabolites (methanol phase), and
69 metabolites in total were detected in tumour tissue
samples (Table 4). We also evaluated the non-water-
soluble metabolites (lipids) present in the chloroform
phase (Fig. 4). In order to assess the effect of the
leucine-rich diet on tumour metabolism, we compared
metabolites present in tumour tissue from the W and
LW groups. Of the 69 water-soluble metabolites, only
glycerol differed between the two groups and was found
a decrease for LW in comparison to W (Table 4). The
non-water-soluble phase revealed that the tumours of
the animals fed with a leucine-rich diet had increased
lipid deposits, with substantial differences between both
groups. In particular, the LW group exhibited increased
values (P ≤ 0.05) of cholesterol and a fatty acyl chain in
comparison to the W group (Fig. 4).
Discussion
The present work utilised 1H NMR to develop metabo-
lomic profiles for all four rat groups to better under-
stand the effect of leucine supplementation on tumour
growth. Profound metabolic changes were observed in
W and LW groups, especially related to protein and
amino acid metabolism. These changes were likely asso-
ciated with a cachexia state induced by an increase in
protein degradation to support tumour growth. Both
tumour-bearing groups also exhibited alterations in spe-
cific pathways related to the metabolism of glycine,
serine, threonine, arginine and proline. These pathways
might be involved in the high activity of tumour cells
and specific host (e.g., muscle) tissues. Moreover, the al-
tered metabolites are those that play a role in amino acid
synthesis (aminoacyl t-RNA biosynthesis) [40], and these
may likely provide newly synthesised amino acids for a
different metabolic pathway, such as gluconeogenesis, or
these amino acids could be directly used by the tumour
tissue as an energy source. Increased body protein turn-
over is normally related to tumour growth [1, 5, 41],
where decreased protein synthesis and increased protein
degradation occur in response to tumour effects that
mobilise muscle proteins. The nitrogen from muscle tis-
sue is a source of building blocks for rapidly growing tu-
mours such as the Walker 256 tumour [27, 34]. Indeed,
high serum levels of 3-methylhistidine, a product of pep-
tide bond synthesis and the methylation of actin and
myosin, was detected in both tumour-bearing groups,
and the corresponding quantity of 3-methylhistidine
provides an index for the rate of muscle protein break-
down [42]. Researchers have previously shown a positive
correlation between increased 3-methylhistidine and can-
cer progression, along with cancer cachexia, due to the
high muscle protein breakdown [43]. In agreement with
this result, we observed that serum levels of creatine and
creatinine were elevated in both tumour-bearing groups
relative to the control groups, and the metabolites 3-
Table 3 Serum metabolic concentration (μM) (Continued)
Pyruvate 68.9 ± 17.5 76.3 ± 31.9 63.1 ± 25.2 71.6 ± 20.0
Sarcosine 0.7 ± 0.1 2.9 ± 0.4 * 0.8 ± 0.5 2.6 ± 1.2 *, ***
Serine 97.3 ± 3.8 46.6 ± 16.0 * 77.8 ± 30.4 43.4 ± 17.6 *, ***
Succinate 37.8 ± 5.5 36.7 ± 14.3 42.4 ± 23.1 52.2 ± 44.5
Taurine 249.0 ± 32.7 227.2 ± 44.6 205.5 ± 71.3 261.8 ± 142.7
Threonine 178.3 ± 40.8 77.4 ± 29.3 * 166.6 ± 77.2 65.3 ± 27.3 *, ***
Tryptophan 1.5 ± 0.3 10.9 ± 2.8 * 1.6 ± 0.7 6.0 ± 2.7 *, **, ***
Tyrosine 31.1 ± 6.0 47.2 ± 9.4 22.3 ± 6.1 38.6 ± 18.6
Uracil 4.1 ± 1.1 10.0 ± 3.8 4.5 ± 0.9 9.1 ± 4.2
Urea 522.7 ± 92.1 1022 ± 400.3 492.2 ± 136.5 2701.1 ± 1817.3 *, **, ***
Valine 75.1 ± 6.8 51.5 ± 10.4 50.9 ± 13.6 52.8 ± 19.5
Myoinositol 22.7 ± 1.7 98.0 ± 11.0 21.6 ± 6.4 153.6 ± 88.3 *, ***
sn-Glycerol-3-phosphocholine 3.3 ± 0.8 5.7 ± 1.4 3.4 ± 0.6 6.2 ± 4.3
3-Methylhistidine 0.0 ± 0.0 12.3 ± 4.4 * 0.0 ± 0.0 17.9 ± 10.3 *, ***
Data are expressed as the mean ± SD. For details, see the Methods and Results sections *P ≤ 0.05 in comparison with the C group; **P ≤ 0.05 in comparison with
the W group and ***P ≤ 0.05 in comparison with the L group




Fig. 2 (See legend on next page.)
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methylhistidine and creatine were even higher in LW
group compared to W group (Table 3). Moreover, while
those protein subproducts were elevated in LW group, this
not reflected in cachexia index which trended to be lower
in the LW group than in the W group (P = 0.0561). These
results suggest that leucine supplementation may be cap-
able of stimulating protein synthesis and, consequently,
may lead to a positive protein net balance even amidst a
high rate of protein degradation, as shown in our previous
studies [44, 45]. The impacted metabolic pathways deter-
mined here also suggest that the leucine-rich group may
divert the metabolism to improve protein synthesis and
also utilised other substrates as energy sources. Further-
more, a significant increase in the tryptophan serum levels
(See figure on previous page.)
Fig. 2 Impacted metabolic pathways and changed metabolites in tumour-bearing rats (W and LW groups) compared to non-tumour-bearing animals (C
and L groups). a Summary of significantly impacted pathways (P≤ 0.05) analysed by the different metabolites found in the leucine group in comparison
to the C group. b Comparison of tumour-bearing rats fed with normal diet (W) and the C group with a serum list of increased and decreased metabolites
levels in W group. Metabolite set enrichment analysis revealed the affected pathways. c Comparison of tumour-bearing rats (LW) and non-tumour-
bearing rats (L) fed a leucine-rich diet with a list of serum metabolites, which both increased and decreased in the LW group serum. Metabolite set
enrichment analysis revealed the affected pathways. d Comparison between both tumour-bearing rats fed a normal diet (W) and a leucine-rich diet (LW)
with a list of metabolites that increased and decreased in the LW serum compared to the W serum. All data were processed using the Metaboanalyst tool





Fig. 3 The most significant metabolites changed in both tumour-bearing groups. a Region of 600 MHz liquid 1H NMR spectra showing β-
hydroxybutyrate metabolite in the serum from W and LW groups. b Region of the 600 MHz liquid 1H NMR spectra showing the acetoacetate
metabolite. c Region of 600 MHz liquid 1H NMR spectra of acetone metabolite. d Region of 600 MHz liquid 1H NMR spectra showing lactate
metabolite in the serum of tumour-bearing rats. The graphics express the results obtained from the area under the curve of spectral regions and
are expressed as the mean ± SD.* P≤ 0.05 for comparison with the W group. For details, see Methods
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for the W group in comparison to LW group sug-
gests that the consumption of a leucine-rich diet may
be associated with a lower tryptophan serum content,
correspondingly lower serotonin levels and thus a de-
creased anorexigenic effect [14, 21, 23, 24, 45] and
cachexia-associated fatigue state [46].
Tumour cells require a large energy supply to grow
and exhibit a special mechanism for nutrient uptake,
preferentially utilising glucose and glutamine as energy
sources [47]. Thus, as might be expected, our data re-
vealed that serum glucose level decreased in both W
and LW groups, and consequently the serum ketone
body levels (β-hydroxybutyrate, acetone and acetoace-
tate) also increased in these groups. In addition to this
low serum glucose content, the ketogenic metabolites
phenylalanine and tyrosine [48, 49] likely contributed to
the serum elevation of ketone bodies observed in both
groups, although the elevation was more pronounced in
the LW group (Table 3). This observation might be
explained by considering that for metabolism in a
Table 4 Tumour tissue metabolic concentration (μM)
Metabolites W (average ± SD) LW (average ± SD)
2-Aminobutyrate 16.9 ± 7.3 13.0 ± 5.7
2-Hydroxybutyrate 12.3 ± 4.1 10.4 ± 5.1
2-Hydroxyisovalerate 6.6 ± 2.6 5.4 ± 3.1
3-Hydroxybutyrate 52.9 ± 47.0 49.7 ± 37.3
3-Hydroxyisobutyrate 6.1 ± 1.7 7.5 ± 2.8
4-Hydroxyphenyllactate 1.6 ± 0.5 2.0 ± 1.0
ADP 16.3 ± 4.3 17.8 ± 8.7
AMP 65.6 ± 39.9 77.3 ± 29.4
Acetate 62.5 ± 12.9 57.3 ± 22.3
Acetone 1.5 ± 1.0 1.6 ± 0.6
Alanine 889.6 ± 477.7 813.7 ± 377.2
Anserine 47.2 ± 29.1 28.2 ± 18.0
Ascorbate 91.3 ± 42.9 87.8 ± 40.5
Asparagine 78.9 ± 35.8 66.1 ± 22.9
Aspartate 106.8 ± 54.5 84.4 ± 40.2
Betaine 56.6 ± 33.8 50.2 ± 29.8
Carnitine 24.8 ± 14.1 22.8 ± 8.1
Choline 22.7 ± 6.2 20.5 ± 10.8
Creatine 118.7 ± 53.2 147.6 ± 82.4
Cytidine 13.0 ± 5.3 11.8 ± 5.7
Dimethylamine 2.2 ± 1.0 1.7 ± 1.4
Ethanol 3.3 ± 1.5 5.3 ± 2.7
Formate 13.4 ± 4.6 10.4 ± 5.4
Fumarate 7.2 ± 1.8 7.4 ± 2.5
Glucose 26.3 ± 11.5 31.1 ± 11.8
Glutamate 541.2 ± 210.0 536.0 ± 208.1
Glutamine 67.8 ± 49.3 54.5 ± 31.7
Glutathione 17.8 ± 8.4 19.6 ± 11.3
Glycerol 46.8 ± 10.6 35.0 ± 7.0*
Glycine 534.3 ± 302.2 466.5 ± 170.9
Guanosine 2.3 ± 1.0 2.0 ± 0.8
Histidine 39.0 ± 15.1 36.2 ± 13.5
Hypoxanthine 31.6 ± 9.0 23.7 ± 8.5
Inosine 61.3 ± 26.2 55.4 ± 23.8
Isoleucine 42.7 ± 16.7 35.0 ± 11.9
Lactate 3193.4 ± 1295.5 3390.1 ± 1713.1
Leucine 86.8 ± 30.2 102.9 ± 56.4
Lysine 168.6 ± 58.1 164.0 ± 76.5
Malate 81.2 ± 24.6 71.5 ± 31.6
Methionine 35.1 ± 16.4 24.5 ± 9.6
N, N-Dimethylglycine 1.6 ± 0.6 2.1 ± 0.8
Niacinamide 19.8 ± 6.2 16.8 ± 5.5
O-Acetylcarnitine 8.8 ± 1.8 8.9 ± 4.7
O-Phosphocholine 206.0 ± 86.2 219.2 ± 77.5
Table 4 Tumour tissue metabolic concentration (μM)
(Continued)
O-Phosphoethanolamine 516.4 ± 206.1 447.2 ± 194.8
Ornithine 9.5 ± 3.5 10.7 ± 3.0
Oxypurinol 669.6 ± 457.5 688.7 ± 433.6
Phenylalanine 52.1 ± 24.6 40.9 ± 13.9
Proline 264.1 ± 101.0 254.6 ± 106.7
Propionate 3.7 ± 1.4 4.2 ± 1.7
Sarcosine 4.5 ± 2.5 4.0 ± 2.4
Serine 129.6 ± 50.2 121.6 ± 56.6
Succinate 78.5 ± 42.3 84.9 ± 43.3
Taurine 750.7 ± 165.6 832.3 ± 297.0
Threonine 146.8 ± 60.3 190.9 ± 125.8
Tryptophan 18.6 ± 7.0 14.8 ± 5.1
Tyrosine 69.5 ± 35.5 50.4 ± 18.3
UDP-N-Acetylglucosamine 17.4 ± 7.9 15.1 ± 6.1
UDP-galactose 6.5 ± 2.2 6.7 ± 1.9
UDP-glucose 11.4 ± 2.7 15.2 ± 5.2
Uracil 25.5 ± 5.9 20.5 ± 6.5
Uridine 14.1 ± 5.0 12.9 ± 5.3
Valine 88.7 ± 33.4 75.9 ± 26.5
Myoinositol 81.4 ± 31.4 79.1 ± 40.5
sn-Glycero-3-phosphocholine 64.8 ± 33.8 80.4 ± 45.3
β-Alanine 16.6 ± 6.3 19.5 ± 5.3
3-Methylhistidine 16.6 ± 10.5 20.1 ± 16.6
τ-Methylhistidine 3.9 ± 1.2 5.4 ± 3.5
Data are expressed as the mean ± SD. For details, see the Methods and
Results sections
*P ≤ 0.05 in comparison with the W group
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glucose-poor environment, excess leucine could also act
as a ketone precursor and promote elevated blood levels
[48, 49]. The ketone bodies could accordingly provide
additional energy to the LW skeletal muscle and host
tissues that is not available to the W group. Besides act-
ing as a fuel source to supply energy for cellular activity
of various tissues, ketone bodies, especially acetoacetate
(AA), can also promote muscle cell proliferation [50],
probably justifying the benefits found in LW group.
Recently, Zou and colleagues (2016) found a novel func-
tion to AA in promoting muscle cell proliferation. AA
accelerates muscle regeneration and ameliorates muscle
dystrophy, acting through activation of the MEK1-
ERK1/2-cyclin D1 pathway, revealing a novel mechanism
in which AA serves as a signalling metabolite in muscle
cell function [50]. We note that there was an inexplic-
able (though not statistically significant) increase in
acetone levels in the W group, which might also act as a
source of enhanced ketogenesis [51]. While healthy cells,
such as skeletal muscle cells, readily adapt to use ke-
tones as an efficient energy substrate, some cancers cells
do not exhibit this metabolic flexibility [52–54]. For
instance, some neoplastic cells lack certain key mitochon-
drial enzymes and have thus a decreased ability to metab-
olise ketone bodies for energy production [53, 55–57]. In
a study of Walker 256 tumour cells, Fearon and collabora-
tors [58] measured the three major enzyme activities
responsible for the metabolism of ketone bodies in the
mitochondria and observed no activity of the enzyme 3-
ketoacid-CoA transferase, aside from significant amounts
of 3-hydroxybutyrate dehydrogenase and acetyl-CoA ace-
tyltransferase. Our data revealed that even with the high
availability of β-hydroxybutyrate and acetoacetate in
serum from the LW group, the tumour size remained
the same between W and LW groups. Thus, we
hypothesise that mitochondrial enzymatic deficiency or
a
b
Fig. 4 a 1H NMR spectrum of apolar tumour tissue metabolites extracted with chloroform from W and LW groups. b Table describing the apolar
metabolites found in both tumour-bearing groups. The identified numbers in the spectrum are described in the table attached to the figure.
Legend: W, tumour-bearing (blue lines); LW, leucine-treated tumour-bearing group (red lines). The results are expressed as the mean ± SD.*
P ≤ 0.05 for comparison with the W group. For details, see Methods
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some structural/functional mitochondrial damage likely
impaired the ability of the Walker 256 tumour cells to
metabolise ketone bodies as an extra energy source.
Ongoing work in our laboratory is endeavouring to
confirm and elucidate this proposed tumour cell defi-
ciency. We note that in support of this argument, a re-
cent study showed that when glioma-bearing rats were
fed a ketogenic diet, tumour growth was unaffected
even with a normal ketone body metabolism in RG2
and 9L gliomas cells and an upregulation of ketone
body transport [59].
In spite of their tumours, the LW group was observed
to maintain a serum leucine content, which was slightly
elevated compared to the W group (Table 3). The ab-
sence of elevated of leucine levels in LW, as observed in
the L group, may be partially explained by considering
that leucine is a ketogenic amino acid. Thus, the most
affected pathway in the tumour-bearing rats appears to
be the synthesis of ketone bodies, and the excess leucine
consumed by the LW group was rapidly deviated to this
pathway (Fig. 5).
Most of the cancer cells exhibit a dysregulated metabolic
phenotype characterised by lactate fermentation in the
presence of oxygen, a phenomenon known as Warburg
effect [60–62]. The conversion of glucose to pyruvate in
neoplastic cells plays a major role in this rapid cellular
growth, as it provides several intermediates required for
biomass synthesis by routeing the carbon flux through the
pentose phosphate pathway [47, 63, 64]. Furthermore, the
conversion of pyruvate to lactate leads to acidosis in
tumour microenvironments, which facilitates the invasion
and metastasis of these cancer cells [65]. As previously
observed in the literature, we found increased lactate
serum levels in the W group in comparison to the control
group, C. This lactate produced from tumour cells also
might be converted to glucose by the Cori cycle (futile
cycle) in the liver [64, 66], a process that contributes to hy-
permetabolism and consequently the wasting of host tis-
sue. As demonstrated by a decrease in serum lactate levels
for the LW group, probably this futile cycle was minimised
in tumour-bearing rats fed a leucine-rich diet and there-
fore leucine supplementation may improve the host tissue
activity minimising the tumour-induced wasting effects.
The tumour-bearing rats also generally showed in-
creases in metabolic pathways that provide nutrient and
energy sources for tumour cell growth. The LW group
recruited various metabolic pathways (such as ketone
body metabolism) that have the potential to increase
tumour cell activity (i.e., enhancing Ki-67 and mTOR
expression), however, the nutritional supplementation
did not appear to benefit tumour growth (Fig. 5). Based
on the 1H NMR-derived metabolomic profiles, we found
that tumour tissue from the LW group had a higher
content of lipid deposits in comparison to tumour tissue
from the W group. This result suggests a reduction in
the ß-oxidation of fatty acids in the Walker 256 cells
treated with leucine. In agreement with these results, Shen
and colleagues [8] have attributed changes of a metabolo-
mic profile in the urine of Walker 256 tumour-bearing
rats to the elevated cell proliferation and reduction in ß-
oxidation of fatty acids during cancer progression.
Our results also revealed two potential candidate serum
biomarkers for Walker 256 tumour growth, namely 3-
methyl-2-oxovaleric acid and 4-hydroxyphenyllactate that
were exclusively detected in serum from tumour-bearing
groups. The metabolite 3-methyl-2-oxovaleric acid is the
alpha-keto acid analogue of isoleucine, produced from iso-
leucine by cytosolic branched-chain aminotransferase 1,
which is a clinical marker of maple syrup urine disease
(MSUD) [42]. Notably, until now no research has shown
that this metabolite is related to cancer evolution. The
other potential candidate biomarker is 4-hydroxypheny
Fig. 5 Proposed mechanism of leucine-rich diet leading to ketosis. TCA: tricarboxylic acid cycle
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llactate (the L-form), which is a tyrosine metabolite and
can be employed to decrease ROS (reactive oxygen spe-
cies) production in both mitochondria and neutrophils.
Therefore, this metabolite might act as a natural antioxi-
dant [42] especially in the tumour-bearing group under a
leucine supplementation effect, although again until now
no research protocol has related hydroxyphenyllactate
with cancer evolution. Furthermore, the high level of
sarcosine found in both tumour-bearing groups could in-
dicate the metastatic potential of this Walker 256 tumour,
as sarcosine is considered to be an oncometabolite due to
its capacity to induce the invasion of cancer cells into
other tissues [67].
Conclusion
Ultimately, a leucine-rich diet implemented to prevent
skeletal muscle loss and ameliorate cachexia in Walker
256 cancer rat hosts had no effect on the tumour
growth. As determined by solution-phase 1H NMR, sup-
plementation did lead to metabolomic alterations that
could partially explain the positive effects of leucine sup-
plementation in the rats. In particular, our data suggest
that a leucine-rich diet drives metabolomic changes,
such as lower levels of tryptophan and lactate (as seen in
the LW group), may be associated with a decreased hy-
permetabolic state and therefore indirectly contribute to
minimise the cachexia. Also, the high availability of β-
hydroxybutyrate and acetoacetate in the LW group
could potentially provide an efficient energy source for
skeletal muscle, which also may indirectly contribute to
the prevention of cachexia. Although some studies have
demonstrated that leucine supplementation may in fact
increase cell signalling and tumour cell proliferation
[68], here we showed that leucine-rich diet has no effect
on tumour evolution. Additional experiments and stud-
ies are ongoing in our laboratory to better understand
the effect of leucine supplementation on tumour tissue
and Walker 256 cell metabolism.
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